United States was Petros Pharmaceuticals’s largest region in fiscal 2024, bringing in $4.04M of $5.11M (79%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2024 |
|---|---|---|---|---|
| United States | $6.57M | $4.80M | $4.04M | |
| International | $1.24M | $1.19M | $1.07M | |
| Total | $7.81M | $5.99M | $5.11M |
Petros Pharmaceuticals brought in $5.11M from its two regions in fiscal 2024, the year ended December 31, 2024. That was down 14.7% from $5.99M in fiscal 2022, the previous year with figures. United States was the largest at $4.04M (79.1%), ahead of International at $1.07M (20.9%).
Compared with fiscal 2022, the previous year with figures, International fell 10.4% to $1.07M and United States fell 15.8% to $4.04M. From fiscal 2021 to 2024, combined revenue from these regions fell from $7.81M to $5.11M, a compound annual decline of 13.2%. United States' share of the total fell from 84.1% to 79.1%.
Medical Devices was Petros Pharmaceuticals’s largest segment in fiscal 2024, bringing in $3.15M of $5.11M (62%).
| Statement Business Segments | FY 2020 | FY 2021 | FY 2022 | FY 2024 |
|---|---|---|---|---|
| Prescription Medications | $4.61M | $2.73M | $1.96M | |
| Prescription Medication Sales | — | — | — | |
| Medical Devices | $3.21M | $3.26M | $3.15M | |
| Medical Device Sales | — | — | — | |
| Total | $7.81M | $5.99M | $5.11M |
Petros Pharmaceuticals brought in $5.11M from its two segments in fiscal 2024, the year ended December 31, 2024. That was down 14.7% from $5.99M in fiscal 2022, the previous year with figures. Medical Devices was the largest at $3.15M (61.6%), ahead of Prescription Medications at $1.96M (38.4%).
Compared with fiscal 2022, the previous year with figures, Medical Devices fell 3.3% to $3.15M and Prescription Medications fell 28.3% to $1.96M. From fiscal 2021 to 2024, combined revenue from these segments fell from $7.81M to $5.11M, a compound annual decline of 13.2%. Medical Devices' share of the total rose from 41.0% to 61.6%.
Petros Pharmaceuticals (PTPI) reports its revenue by geography and by statement business segments. In fiscal 2024, United States was its largest region, bringing in $4.04M (79.1% of the total), followed by International at $1.07M (20.9%).
United States was Petros Pharmaceuticals' largest region in fiscal 2024, bringing in $4.04M, or 79.1% of the $5.11M total across its two regions.
Medical Devices was Petros Pharmaceuticals' largest segment in fiscal 2024, bringing in $3.15M, or 61.6% of the $5.11M total across its two segments.
Every figure comes from Petros Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Petros Pharmaceuticals gives it, and years follow its fiscal calendar.
Petros Pharmaceuticals' revenue by geography goes back to fiscal 2020, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.